Royce & Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.5M | Buy |
283,187
+35,329
| +14% | +$811K | 0.07% | 409 |
|
|
2025
Q1 | $7.19M | Buy |
247,858
+238,956
| +2,684% | +$6.93M | 0.08% | 375 |
|
|
2024
Q4 | $331K | Sell |
8,902
-174
| -2% | -$6.46K | ﹤0.01% | 784 |
|
|
2024
Q3 | $440K | Hold |
9,076
| – | – | ﹤0.01% | 807 |
|
|
2024
Q2 | $363K | Buy |
+9,076
| New | +$363K | ﹤0.01% | 813 |
|
|
2023
Q2 | – | Sell |
-22,315
| Closed | -$837K | – | 915 |
|
|
2023
Q1 | $837K | Buy |
+22,315
| New | +$837K | 0.01% | 787 |
|
|
2022
Q3 | – | Sell |
-13,546
| Closed | -$471K | – | 933 |
|
|
2022
Q2 | $471K | Sell |
13,546
-7,354
| -35% | -$256K | ﹤0.01% | 840 |
|
|
2022
Q1 | $750K | Buy |
20,900
+894
| +4% | +$32.1K | 0.01% | 836 |
|
|
2021
Q4 | $466K | Buy |
+20,006
| New | +$466K | ﹤0.01% | 899 |
|